Further, the application of the BV-[CMV-NTR-EGFP] transduction/pro-drug conversion system as a low toxicity means to presensitise prostate tumours to the effects of radiation, an approach referred to by Hanna et al[60], could be a complementary clinical approach. This evidence concerns the gene NTSR1 and prostate neoplasm.